Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBITDA (2021 - 2025)

Historic EBITDA for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $18.3 million.

  • Kiniksa Pharmaceuticals International's EBITDA rose 24545.38% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 49310.5%. This contributed to the annual value of -$43.4 million for FY2024, which is 40871.42% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's EBITDA stood at $18.3 million, which was up 24545.38% from $17.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's EBITDA's 5-year high stood at $224.1 million during Q3 2022, with a 5-year trough of -$49.5 million in Q1 2021.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median EBITDA value was -$12.3 million (recorded in 2023), while the average stood at $2.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 83201.27% in 2022, then tumbled by 13569.16% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBITDA (Quarter) stood at -$36.4 million in 2021, then soared by 112.58% to $4.6 million in 2022, then skyrocketed by 451.78% to $25.2 million in 2023, then plummeted by 135.69% to -$9.0 million in 2024, then soared by 303.47% to $18.3 million in 2025.
  • Its EBITDA stands at $18.3 million for Q3 2025, versus $17.9 million for Q2 2025 and $8.5 million for Q1 2025.